In this phase, consecutive emergency department patients with GBS low-risk criteria (GBS =0) were identified and managed as outpatients. All patients who were discharged from one hospital and ...

Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...